

**Supplemental Table 1. Changes of traditional lipids, PON activity, and oxylipins from baseline to six months by treatment group.**

	<b>TNFi</b>	<b>RTX</b>	<b>ABA</b>	<b>TCZ</b>
<b>Traditional Lipids</b>	<b>N=420</b>	<b>N=112</b>	<b>N=359</b>	<b>N=284</b>
<b>TC<sup>^</sup> (mg/dL)</b>	1.3(1.4)	0.04(2.8)	0.5(1.5)	8.4(2.0)*
<b>LDL<sup>^</sup> (mg/dL)</b>	0.9(1.3)	0.3(2.4)	-0.6(1.3)	6.8(1.8)*
<b>HDL<sup>^</sup> (mg/dL)</b>	0.8(0.6)	0.5(1.1)	0.2(0.5)	1.6(0.8)*
<b>TG<sup>^</sup> (mg/dL)</b>	2.1(3.8)	5.0(7.6)	5.4(3.4)	14.7(5.6)*
<b>PON1 Activity</b>	<b>N=379</b>	<b>N=111</b>	<b>N=330</b>	<b>N=272</b>
<b>PON<sup>#</sup></b>	1.2(5.7)	-7.5(10.2)	3.7(6.5)	30.3(8.3)*
<b>LAC<sup>#</sup></b>	15.0(8.4)	1.5(11.7)	-0.2(8.2)	41.9(9.5)*
<b>ARYL<sup>#</sup></b>	10.9(7.6)	16.9(12.1)	3.9(8.8)	29.8(8.2)*
<b>Oxylipins</b>	<b>N=83</b>	<b>N=92</b>	<b>N=82</b>	<b>N=92</b>
<b>6k PGF1<math>\alpha</math><sup>%#</sup></b>	0.5(1.5)	-2.4(1.4)	-2.4(1.6)	-2.4(1.4)
<b>TXB2<sup>%#</sup></b>	79.7(35.7)*	39.7(29.2)	2.5(33.3)	-14.2(29.1)
<b>PGE2<sup>%#</sup></b>	13.4(11.3)	-5.4(6.6)	25.5(14.7)	-4.4(2.7)
<b>LXA4<sup>%#</sup></b>	8.9(9.1)	-2.2(7.3)	15.9(12.1)	-8.9(3.8)*
<b>RvD1<sup>%</sup></b>	1.9(1.1)	0.3(0.8)	1.8(1.6)	-1.0(0.7)
<b>13,14-dihydro-15k PGF2<math>\alpha</math><sup>%</sup></b>	1.1(1.0)	-0.07(0.9)	2.0(2.9)	1.2(0.9)
<b>6trans12epi LTB4 + LTB4<sup>%#</sup></b>	-13.3(8.3)	-5.8(17.9)	75.6(36.3)*	-16.8(8.2)*
<b>13HODE<sup>%</sup></b>	20.0(26.5)	9.4(20.6)	111.4(49.5)*	-61.1(21.1)*
<b>9HODE<sup>%</sup></b>	22.0(27.3)	9.8(21.7)	121.3(50.4)*	-77.7(21.1)*
<b>15HETE<sup>%</sup></b>	26.4(22.7)	5.8(17.2)	96.6(42.8)*	-36.0(14.7)*
<b>14S-HDHA<sup>%</sup></b>	23.9(24.8)	3.7(16.1)	51.1(36.2)	-15.5(12.5)
<b>(14S-HDoHE)</b>				
<b>11HETE<sup>%</sup></b>	27.6(23.4)	8.0(17.9)	103.8(43.9)*	-44.9(15.9)*
<b>12HETE<sup>%</sup></b>	14.0(52.0)	2.4(41.1)	-1.4(53.8)	-64.1(42.6)
<b>5HETE<sup>%</sup></b>	32.0(42.0)	11.8(31.5)	165.9(62.5)*	-101.4(36.4)*
<b>5-oxoETE<sup>%</sup></b>	13.5(14.7)	-2.1(13.2)	68.2(29.5)*	-26.8(8.3)*

Values are mean (SEM)

Values represent differences from baseline to 6 months (6 month minus baseline)

<sup>^</sup>N=1,175

<sup>#</sup>PON1 values transformed by  $\text{Log}_{10}(x)$ ; values reported as  $\text{Log}_{10}(x) * 10^3$  (N=1090-1091). Units are  $\text{Log}(U/mL)$

<sup>%</sup>oxylipin values transformed by  $\text{Log}_{10}(x+1)$ ; values reported as  $\text{Log}_{10}(x+1) * 10^3$  (N=204-350 across each oxylipin). Units are  $\text{Log}(ng/mL)$ .

<sup>#</sup>Additional missingness of data in these oxylipins with lower sample sizes compared to non-marked oxylipins. Missing data was due to technical issues with sample processing.

\*Mean change is significant different from zero by paired t-test,  $p < 0.05$